Sam Altmans longevity startup is upping the dose in an Alzheimers drug trial after a lackluster first round
News Source : Business Insider
News Summary
- Retro Biosciences is testing a longevity pill that the company hopes could one day fight dementia.
- The pill is designed to jump-start key cellular recycling processes in the body, which stall as we get older.
- RTR 242 has already been in clinical trials in Australia for several months.
- If the trial is successful, it could pave the way for Altman's longevity startup to edge ahead in the schoolyard competition among Silicon Valley billionaires: Who can deliver a moonshot longevity drug first?
Joe BettsLaCroix is the CEO of Retro Biosciences, a longevity biotech company backed by Sam Altman.
Never miss a story from us, subscribe to our newsletter